Google
Trusted Resources: News & Events
Latest announcements and gatherings
FDA Awards UNC Researcher $2M Grant to Study Kidney Disease in Sickle Cell Anemia
The U.S. Food and Drug Administration (FDA) has awarded Dr. Kenneth Ataga, a $2 million grant over five years to support a prospective study in sickle cell anemia to determine biomarkers of specific cellular function changes in chronic kidney disease (CKD).
Ataga, a researcher with the University of North Carolina at Chapel Hill, published the results of a Phase 2 SUSTAIN clinical trial (NCT01895361) in December 2016. The trial demonstrated that the anti-P-selectin antibody crizanlizumab (SEG101), developed by Selexys Pharmaceuticals and Novartis, reduced the median annual rate of sickle cell-related pain crises by 45.3 percent, when compared to placebo.
+myBinderRelated Content
-
Vitamin D Supplements May Reduce Pain-related Emergency Room Visits in Children With SCDTaking vitamin D supplements may lower t...
-
8 Tips to Support Students With Sickle Cell DiseaseIn the United States, sickle cell diseas...
-
Sickle Cell Disease: After Years of Neglect Some Promise for SufferersIt’s Black History Month, when the nat...
-
Capitol Hill Briefing Held to Encourage Sickle Cell Research and TreatmentEarlier today, a briefing was hosted on ...
-
Scientists edit genome to cure sickle cell anemiahttps://www.youtube.com/watch?v=4LKzM3G6...
-
New Guidelines for Managing Sickle Cell Disease Presented at ACP Internal Medicine MeetingNew guidelines for therapeutic strategie...
-
Effects of Rifaximin on Circulating Aged Neutrophils in Sickle Cell DiseaseThere is a large therapeutic gap in sick...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.